Therefore, intra-tumoral heterogeneity as a partial reason for MGMT promoter methylation changes cannot be excluded and therapy-induced eradication of sensitive tumor clones and clonal expansion of resistant ones may be involved in this phenomenon. Here, MGMT is linked to neoplasm.